AbbVie Presents Results of Imbruvica (ibrutinib) + Venclexta/Venclyxto in P-III GLOW Study as 1L Treatment for CLL or SLL at EHA 2021
Shots:
- The P-III GLOW study evaluates Imbruvica + Venclexta/Venclyxto (I+V) vs chlorambucil + obinutuzumab (C+O) in 211 patients in a ratio (1:1) aged ≥65yrs. with CLL/SLL
- The study met its 1EPs of PFS as assessed by IRC & showed a 78% reduction in risk of disease progression or death- mPFS (not reached vs 21mos.) & safety profile of the combination was consistent with the safety profile of monothx. & tolerability profiles were consistent with CLL treatment in a patient population
- The 2EPs includes uMRD (51.9% vs 17.1%) @3mos.- PB uMRD (49% vs 12%) @12mos.- CR rate (38.7% vs 11.4%)- ORR was not different b/w treated groups- time to subsequent therapy was longer for I+V
| Ref: Abbvie | Image: abbvie
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com